Effect Of DC-CIK On Clinical Curative Effect And Living Condition Of Patients With Lung Cancer With Deficiency Of Qi And Yin Deficiency

Purpose:This study was designed to investigate the clinical efficacy of DC-CIK Qi Deficiency of lung cancer(Non small cell lung cancer, NSCLC) patients, survival time,survival improvement of quality and adverse reactions.Material and method:The Qi Deficiency among lung cancer patients from September2013 to March 2014 in our hospital 46 cases, expected survival time> 3 months, 36 males,mean age 48.97 ± 16.53 years, 10 females, mean Age 58.40 ± 15.31 years. Patients and their families according to their own requirements, divided into treatment group and control group,the treatment group of 23 patients, mean age 53.08 ± 16.53 years, the control group of 23 patients, mean age 52.97 ± 14.78 years, the treatment group received DC-CIK combined with KLT fluid control group alone KLT treatment group and the control group on the first day while starting intravenous KLT 100 m L / d, once every 21 d, this is a course of treatment;treatment group injection Combined DC-CIK treatment, patients treated before applying KLT from its own collection of blood, lymphocytes were isolated, cultured in vitro culture 14-15 d after intravenous transfusion, continuous transfusion twice a day, once a reinfusion this is a course of treatment. Clinical Evaluation of the two groups of patients, side effects and quality of life after the completion of at least two courses. Periodic review of follow-up, at least three months to assess the review time, until disease progression occurs. The clinical observation of patients with tumor response rate(RR), clinical benefit rate(CBR), the median survival time(MST), quality of life and adverse reactions。Results:1. RR of the treatment group and the observation group were 26.1% and 4.3%, CBR were78.2% and 34.8%, the difference was statistically significant(P <0.05). 2. MST of the treatment group and the observation group were 14 months and 9 months, there is a statistically significant difference survival time of the two groups(P <0.05).3. The quality of life in the treatment group comparative observation group Karnofsky score overall improvement rate was 86.9% and 56.5%, respectively, the presence of two KPS increased rate difference was statistically significant(P <0.05).4. Two groups of patients with adverse reactions mainly fever, nausea, vomiting, diarrhea,rash, presence of adverse reactions between the two groups the incidence of the difference statistically significant(P <0.05).Conclusion:1. DC-CIK can enhance Qi Deficiency RR of lung cancer patients, CBR.2. DC-CIK can prolong the survival time of patients with lung cancer Qi Deficiency.3. DC-CIK can improve Qi and Yin deficiency of lung cancer patients KPS, said it is possible to improve their quality of life.4. DC-CIK can reduce the incidence of lung cancer Qi Deficiency of adverse reactions.5.DC-CIK combined with KLT to improve the clinical efficacy of Qi and Yin deficiency of lung cancer patients, survival better.